These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 28796564)

  • 41. The rise of biosimilars: How they got here and where they are going.
    Patel D; Gillis C; Naggar J; Mistry A; Mantzoros CS
    Metabolism; 2017 Oct; 75():45-53. PubMed ID: 28939017
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Biosimilars battle rages on, Amgen fights both sides.
    Senior M
    Nat Biotechnol; 2013 Apr; 31(4):269-70. PubMed ID: 23563402
    [No Abstract]   [Full Text] [Related]  

  • 43. [Biosimilars - Potential, risks and open questions].
    Dtsch Med Wochenschr; 2014 Jan; 139(1-2):12-3. PubMed ID: 24551883
    [No Abstract]   [Full Text] [Related]  

  • 44. Biologic product identification and US pharmacovigilance in the biosimilars era.
    Felix T; Johansson TT; Colliatie JA; Goldberg MR; Fox AR
    Nat Biotechnol; 2014 Feb; 32(2):128-30. PubMed ID: 24509751
    [No Abstract]   [Full Text] [Related]  

  • 45. Considerations in the early development of biosimilar products.
    Li EC; Abbas R; Jacobs IA; Yin D
    Drug Discov Today; 2015 May; 20 Suppl 2():1-9. PubMed ID: 25572407
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Assessment of Quality Attributes for Biosimilars: a Statistical Perspective on Current Practice and a Proposal.
    Mielke J; Innerbichler F; Schiestl M; Ballarini NM; Jones B
    AAPS J; 2018 Nov; 21(1):7. PubMed ID: 30483892
    [TBL] [Abstract][Full Text] [Related]  

  • 47. An overview of biosimilars and non-biologic complex drugs in Europe, the United States, and Canada and their relevance to multiple sclerosis.
    Gran-Ruaz S; Mani A; O'Quinn S
    Mult Scler; 2017 Dec; 23(14):1824-1829. PubMed ID: 29095099
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Challenging Future of the Biosimilars Market.
    Joseph E
    J Pharm Pract; 2016 Jun; 29(3):266-7. PubMed ID: 27169735
    [No Abstract]   [Full Text] [Related]  

  • 49. FDA's Gottlieb Aims To End Biosimilars Groundhog Day.
    Kirkner RM
    Manag Care; 2019 Jan; 28(1):5-6. PubMed ID: 30883313
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Friction in the Path to Use of Biosimilar Drugs.
    Frank RG
    N Engl J Med; 2018 Mar; 378(9):791-793. PubMed ID: 29490182
    [No Abstract]   [Full Text] [Related]  

  • 51. Biosimilars: a cure to the U.S. health care cost conundrum?
    Hirsch BR; Lyman GH
    Blood Rev; 2014 Nov; 28(6):263-8. PubMed ID: 25260225
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Coverage for Biosimilars vs Reference Products Among US Commercial Health Plans.
    Chambers JD; Lai RC; Margaretos NM; Panzer AD; Cohen JT; Neumann PJ
    JAMA; 2020 May; 323(19):1972-1973. PubMed ID: 32427297
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Conversation with Gary Lyman, MD: Biosimilars and the Search for the Cure To Cancer Treatment's Financial Toxicity.
    Wehrwein P
    Manag Care; 2019 Jan; 28(1):12-15. PubMed ID: 30883317
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Biosimilars-Curb Your Enthusiasm.
    Yang YT; Chen B; Bennett CL
    JAMA Oncol; 2017 Nov; 3(11):1467-1468. PubMed ID: 28594963
    [No Abstract]   [Full Text] [Related]  

  • 55. [Cheaper with biosimilars, but safety comes first].
    Mellstedt H
    Lakartidningen; 2014 May 27-Jun 10; 111(22-23):1011. PubMed ID: 24946487
    [No Abstract]   [Full Text] [Related]  

  • 56. Price competition and reimbursement of biosimilar granulocyte-colony stimulating factor in Hungary.
    Hornyák L; Nagy Z; Ilku L; Tálos Z; Endrei D; Ágoston I; Csákvári T; Danku N; Répásy B; Boncz I
    Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):725-731. PubMed ID: 30763134
    [No Abstract]   [Full Text] [Related]  

  • 57. On safety margin for drug interchangeability.
    Zheng J; Chow SC; Song F
    J Biopharm Stat; 2017; 27(2):293-307. PubMed ID: 27911675
    [TBL] [Abstract][Full Text] [Related]  

  • 58. State laws on biosimilars may drive up plans' costs.
    Carroll J
    Manag Care; 2013 Apr; 22(4):8-9. PubMed ID: 23682380
    [No Abstract]   [Full Text] [Related]  

  • 59. [Introduction of biosimilars requires careful monitoring].
    Marsal J; Hertervig E
    Lakartidningen; 2016 Mar; 113():. PubMed ID: 26954925
    [No Abstract]   [Full Text] [Related]  

  • 60. The state of the art in the development of biosimilars.
    McCamish M; Woollett G
    Clin Pharmacol Ther; 2012 Mar; 91(3):405-17. PubMed ID: 22318617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.